Jason Rhodes Sells 309,268 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 309,268 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $21.28, for a total value of $6,581,223.04. Following the transaction, the director owned 1,016,633 shares in the company, valued at $21,633,950.24. This represents a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

DYN stock opened at $21.79 on Thursday. The company has a market capitalization of $3.60 billion, a P/E ratio of -6.77 and a beta of 1.06. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The business has a 50 day simple moving average of $18.55 and a 200-day simple moving average of $18.13. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the firm earned ($1.05) earnings per share. As a group, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Wall Street Analyst Weigh In

DYN has been the subject of several recent research reports. TD Cowen started coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating for the company. Sanford C. Bernstein boosted their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. grew its holdings in Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. Orbis Allan Gray Ltd acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Dyne Therapeutics in the 2nd quarter worth about $30,378,000. Perceptive Advisors LLC boosted its position in shares of Dyne Therapeutics by 543.7% in the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after buying an additional 2,938,500 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Dyne Therapeutics by 572.9% in the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock valued at $38,119,000 after acquiring an additional 2,565,570 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.